<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279641</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-107</org_study_id>
    <nct_id>NCT02279641</nct_id>
  </id_info>
  <brief_title>RDEA3170 and Allopurinol Combination Study in Gout Subjects</brief_title>
  <official_title>A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male
      subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics
      (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2014</start_date>
  <completion_date type="Actual">September 11, 2015</completion_date>
  <primary_completion_date type="Actual">April 6, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>22 days</time_frame>
    <description>Cmax of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Occurrence of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>22 days</time_frame>
    <description>Tmax of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</measure>
    <time_frame>22 days</time_frame>
    <description>AUC 0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</measure>
    <time_frame>22 days</time_frame>
    <description>AUC last of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2)</measure>
    <time_frame>22 days</time_frame>
    <description>t1/2 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)</measure>
    <time_frame>22 days</time_frame>
    <description>Ae0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance of the Drug From Time Zero up to 24 Hours Postdose (CRL0-24)</measure>
    <time_frame>22 days</time_frame>
    <description>CLR0-24 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (PD) Profile of Uric Acid From Serum and Urine</measure>
    <time_frame>22 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>22 days</time_frame>
    <description>Cmax of RDEA3170 Alone and In Combination with Allopurinol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</measure>
    <time_frame>22 days</time_frame>
    <description>AUC 0-24 of RDEA3170 Alone and In Combination with Allopurinol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</measure>
    <time_frame>22 days</time_frame>
    <description>AUC last of RDEA3170 Alone and In Combination with Allopurinol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)</measure>
    <time_frame>22 days</time_frame>
    <description>Ae0-24 of RDEA3170 Alone and In Combination with Allopurinol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 10 mg</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol 300 mg</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject meets one or more criteria for the diagnosis of gout as per the American
             Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary
             Gout.

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45
             kg/m2.

          -  Subject has a Screening serum urate level ≥ 8 mg/dL and ≤ 10 mg/dL

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Subject is unable to take colchicine for gout flare prophylaxis.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has an estimated creatinine clearance &lt; 60 mL/min calculated by the
             Cockcroft-Gault formula using ideal body weight at Screening prior to Day -2.

          -  Subject is on unstable doses of chronic medications. Subjects taking medications for
             chronic medical conditions must be on stable doses during the course of the study,
             including the Screening period. Dose adjustments are allowed if deemed medically
             necessary by the investigator and following discussion with the medical monitor

          -  Chronic and stable doses of losartan, fenofibrate, guaifenesin, and sodium-glucose
             linked transporter-2 inhibitors are permitted if the dose is stable for at least 14
             days prior to study medication dosing.

          -  Subject is unable or unwilling to comply with the study requirements or has a
             situation or condition that, in the opinion of the Investigator, may interfere with
             participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <results_first_submitted>March 14, 2017</results_first_submitted>
  <results_first_submitted_qc>December 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 20, 2017</results_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 subjects were randomized</recruitment_details>
      <pre_assignment_details>Twelve subjects were randomized to 1 of 2 treatment sequences (Sequence A or B) in a 1:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RDEA3170 or Allopurinol Alone and in Combination (Sequence A)</title>
          <description>Days 1 to 7: 10 mg once daily (qd) RDEA3170; Days 8 to 14: 10 mg qd RDEA3170 + 300 mg qd allopurinol; Days 15 to 21: 300 mg qd allopurinol</description>
        </group>
        <group group_id="P2">
          <title>RDEA3170 or Allopurinol Alone and in Combination (Sequence B)</title>
          <description>Days 1 to 7: 300 mg qd allopurinol; Days 8 to 14: 10 mg qd RDEA3170 + 300 mg qd allopurinol; Days 15 to 21: 10 mg qd RDEA3170</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence A</title>
          <description>Days 1 to 7: 10 mg once daily (qd) RDEA3170; Days 8 to 14: 10 mg qd RDEA3170 + 300 mg qd allopurinol; Days 15 to 21: 300 mg qd allopurinol</description>
        </group>
        <group group_id="B2">
          <title>Sequence B</title>
          <description>Days 1 to 7: 300 mg qd allopurinol; Days 8 to 14: 10 mg qd RDEA3170 + 300 mg qd allopurinol; Days 15 to 21: 10 mg qd RDEA3170</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="10.1"/>
                    <measurement group_id="B2" value="49" spread="10.4"/>
                    <measurement group_id="B3" value="51" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>Cmax of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Oxypurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O4">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <description>Cmax of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.894" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.24" upper_limit="1.82"/>
                    <measurement group_id="O3" value="12.8" lower_limit="11.7" upper_limit="14.0"/>
                    <measurement group_id="O4" value="8.68" lower_limit="7.99" upper_limit="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>133</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>111</ci_lower_limit>
            <ci_upper_limit>159</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>67.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.2</ci_lower_limit>
            <ci_upper_limit>70.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
        <description>Tmax of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Oxypurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O4">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O5">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O6">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
          <description>Tmax of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O4" value="3.50" lower_limit="1.50" upper_limit="8.00"/>
                    <measurement group_id="O5" value="3.00" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="3.00" lower_limit="2.00" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</title>
        <description>AUC 0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Oxypurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O4">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O5">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</title>
          <description>AUC 0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
          <units>μg·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" lower_limit="3.24" upper_limit="4.21"/>
                    <measurement group_id="O2" value="3.68" lower_limit="3.28" upper_limit="4.13"/>
                    <measurement group_id="O3" value="255" lower_limit="229" upper_limit="284"/>
                    <measurement group_id="O4" value="157" lower_limit="140" upper_limit="177"/>
                    <measurement group_id="O5" value="115" lower_limit="96.5" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>102</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.3</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>61.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.1</ci_lower_limit>
            <ci_upper_limit>65.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>95.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.4</ci_lower_limit>
            <ci_upper_limit>104</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</title>
        <description>AUC last of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Oxypurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O4">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</title>
          <description>AUC last of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
          <units>μg·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="3.04" upper_limit="4.04"/>
                    <measurement group_id="O2" value="3.61" lower_limit="3.22" upper_limit="4.05"/>
                    <measurement group_id="O3" value="255" lower_limit="229" upper_limit="284"/>
                    <measurement group_id="O4" value="157" lower_limit="140" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>103</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.9</ci_lower_limit>
            <ci_upper_limit>112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>61.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.1</ci_lower_limit>
            <ci_upper_limit>65.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2)</title>
        <description>t1/2 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Oxypurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O4">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O5">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O6">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2)</title>
          <description>t1/2 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.969" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.890" upper_limit="1.10"/>
                    <measurement group_id="O3" value="43.2" lower_limit="36.1" upper_limit="51.7"/>
                    <measurement group_id="O4" value="29.1" lower_limit="23.9" upper_limit="35.4"/>
                    <measurement group_id="O5" value="11.5" lower_limit="8.43" upper_limit="15.6"/>
                    <measurement group_id="O6" value="12.5" lower_limit="8.99" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)</title>
        <description>Ae0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Oxypurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O4">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)</title>
          <description>Ae0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170</description>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" lower_limit="22.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="22.7" lower_limit="19.2" upper_limit="26.9"/>
                    <measurement group_id="O3" value="231" lower_limit="216" upper_limit="248"/>
                    <measurement group_id="O4" value="275" lower_limit="262" upper_limit="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>89.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.8</ci_lower_limit>
            <ci_upper_limit>98.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>119</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114</ci_lower_limit>
            <ci_upper_limit>125</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance of the Drug From Time Zero up to 24 Hours Postdose (CRL0-24)</title>
        <description>CLR0-24 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Oxypurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O4">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O5">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O6">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of the Drug From Time Zero up to 24 Hours Postdose (CRL0-24)</title>
          <description>CLR0-24 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination</description>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="106" upper_limit="135"/>
                    <measurement group_id="O2" value="103" lower_limit="87.1" upper_limit="122"/>
                    <measurement group_id="O3" value="15.1" lower_limit="13.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="29.2" lower_limit="25.1" upper_limit="33.9"/>
                    <measurement group_id="O5" value="9.28" lower_limit="7.43" upper_limit="11.6"/>
                    <measurement group_id="O6" value="9.75" lower_limit="7.73" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>87.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.3</ci_lower_limit>
            <ci_upper_limit>96.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>193</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>177</ci_lower_limit>
            <ci_upper_limit>210</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>105</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.4</ci_lower_limit>
            <ci_upper_limit>117</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamics (PD) Profile of Uric Acid From Serum and Urine</title>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics (PD) Profile of Uric Acid From Serum and Urine</title>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Urate Maximum % Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.5" spread="2.43" lower_limit="13.0" upper_limit="17.6"/>
                    <measurement group_id="O2" value="-65.2" spread="1.57" lower_limit="25.1" upper_limit="33.9"/>
                    <measurement group_id="O3" value="-43.0" spread="1.57" lower_limit="7.43" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Uric Acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.88" spread="7.61"/>
                    <measurement group_id="O2" value="-21.6" spread="5.58"/>
                    <measurement group_id="O3" value="-47.4" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Clearance of Uric Acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" spread="46.8"/>
                    <measurement group_id="O2" value="125" spread="42.2"/>
                    <measurement group_id="O3" value="-8.50" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fract. Excretion of Uric Acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" spread="18.0"/>
                    <measurement group_id="O2" value="78.4" spread="21.9"/>
                    <measurement group_id="O3" value="-12.0" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment-Emergent Adverse Events</title>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Oxypurinol: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol: Allopurinol Alone</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events</title>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="2.43" lower_limit="13.0" upper_limit="17.6"/>
                    <measurement group_id="O2" value="1" spread="1.57" lower_limit="25.1" upper_limit="33.9"/>
                    <measurement group_id="O3" value="3" spread="1.57" lower_limit="7.43" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>Cmax of RDEA3170 Alone and In Combination with Allopurinol</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O2">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <description>Cmax of RDEA3170 Alone and In Combination with Allopurinol</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="12.2" upper_limit="17.5"/>
                    <measurement group_id="O2" value="14.5" lower_limit="11.7" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>98.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.7</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</title>
        <description>AUC 0-24 of RDEA3170 Alone and In Combination with Allopurinol</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O2">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</title>
          <description>AUC 0-24 of RDEA3170 Alone and In Combination with Allopurinol</description>
          <units>μg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="98.1" upper_limit="147"/>
                    <measurement group_id="O2" value="115" lower_limit="96.5" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>95.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.4</ci_lower_limit>
            <ci_upper_limit>104</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</title>
        <description>AUC last of RDEA3170 Alone and In Combination with Allopurinol</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O2">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</title>
          <description>AUC last of RDEA3170 Alone and In Combination with Allopurinol</description>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="98.1" upper_limit="147"/>
                    <measurement group_id="O2" value="115" lower_limit="96.5" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>95.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.4</ci_lower_limit>
            <ci_upper_limit>104</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)</title>
        <description>Ae0-24 of RDEA3170 Alone and In Combination with Allopurinol</description>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RDEA3170: RDEA3170 Alone</title>
            <description>RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O2">
            <title>RDEA3170: RDEA3170 + Allopurinol</title>
            <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)</title>
          <description>Ae0-24 of RDEA3170 Alone and In Combination with Allopurinol</description>
          <units>ug</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" lower_limit="51.8" upper_limit="86.1"/>
                    <measurement group_id="O2" value="67.2" lower_limit="51.7" upper_limit="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>101</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.7</ci_lower_limit>
            <ci_upper_limit>117</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 days</time_frame>
      <desc>Overall number of baseline participants used to determine number of participants at risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>RDEA3170 10 mg qd</title>
          <description>RDEA3170 10 mg qd</description>
        </group>
        <group group_id="E2">
          <title>RDEA3170 10 mg qd + Allopurinol 300 mg qd</title>
          <description>RDEA3170 10 mg qd + Allopurinol 300 mg qd</description>
        </group>
        <group group_id="E3">
          <title>Allopurinol 300 mg qd</title>
          <description>Allopurinol 300 mg qd</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jesse Hall, MD</name_or_title>
      <organization>Study Information Center AstraZeneca</organization>
      <phone>+1 877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

